Zymeworks Stock Price Target and Analyst Ratings (NYSE:ZYME)

Analyst Price Target for ZYME

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$51.11

▲ +49.62% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $51.11, with a high forecast of $74.00 and a low forecast of $38.00. The average price target represents a 49.62% upside from the last price of $34.16.

Buy

The current consensus among 10 polled investment analysts is to buy stock in Zymeworks. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/10/2019

1 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/9/2019

1 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/8/2020

1 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/6/2020

1 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/4/2020

1 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/3/2020

1 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/1/2021

1 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/3/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/3/2021	Raymond James	Set Price Target	Strong-Buy	$74.00	Medium	i
3/3/2021	SVB Leerink	Reiterated Rating	Outperform ➝ Market Perform	$50.00 ➝ $41.00	High	i Rating by A. Berens at SVB Leerink LLC
2/25/2021	Raymond James	Set Price Target	Strong-Buy	$74.00	High	i
2/25/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$50.00 ➝ $41.00	High	i Rating by A. Berens at SVB Leerink LLC
2/8/2021	HC Wainwright	Reiterated Rating	Buy	$57.00	Low	i Rating by R. Burns at HC Wainwright
2/3/2021	Raymond James	Set Price Target	Strong-Buy	$74.00	Low	i
1/29/2021	Citigroup	Upgrade	Neutral ➝ Buy		Low	i
1/28/2021	Wells Fargo & Company	Lower Price Target		$71.00 ➝ $56.00	Low	i
1/28/2021	Raymond James	Set Price Target	Strong-Buy	$74.00	Low	i
1/28/2021	SVB Leerink	Lower Price Target	Outperform	$66.00 ➝ $50.00	Low	i Rating by A. Berens at SVB Leerink LLC
1/28/2021	Barclays	Lower Price Target	Equal Weight	$47.00 ➝ $38.00	High	i
1/25/2021	Citigroup	Downgrade	Buy ➝ Neutral	$50.00 ➝ $53.00	High	i
1/19/2021	Raymond James	Boost Price Target	Strong-Buy	$60.00 ➝ $74.00	Medium	i
1/12/2021	Raymond James	Set Price Target	Strong-Buy	$60.00	High	i
1/12/2021	Wells Fargo & Company	Boost Price Target	Overweight	$58.00 ➝ $71.00	High	i
1/12/2021	SVB Leerink	Boost Price Target	Outperform	$45.00 ➝ $66.00	High	i Rating by A. Berens at SVB Leerink LLC
12/2/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Low	i
11/17/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	High	i
11/4/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	High	i
10/26/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Low	i
9/29/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Low	i
8/6/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Medium	i
8/6/2020	SVB Leerink	Initiated Coverage	Outperform	$45.00	Medium	i Rating by A. Berens at SVB Leerink LLC
7/16/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Low	i Rating by David Novak at Raymond James
7/14/2020	Guggenheim	Lower Price Target		$54.00 ➝ $48.00	Low	i
7/13/2020	Canaccord Genuity	Boost Price Target	Buy	$25.00 ➝ $42.00	High	i
7/9/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Medium	i Rating by David Novak at Raymond James
7/9/2020	HC Wainwright	Lower Price Target	Buy	$60.00 ➝ $54.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
6/14/2020	Bloom Burton	Reiterated Rating	Buy		Low	i Rating by D. Martin at Bloom Burton
6/3/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Low	i Rating by David Novak at Raymond James
6/2/2020	Citigroup	Boost Price Target	Buy	$49.00 ➝ $50.00	High	i
5/8/2020	Paradigm Capital	Reiterated Rating	Buy	$51.00	Medium	i Rating by Corey Hammill at Paradigm Capital
5/8/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	High	i Rating by David Novak at Raymond James
5/8/2020	HC Wainwright	Reiterated Rating	Buy	$60.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
4/2/2020	Raymond James	Set Price Target	Strong-Buy	$60.00	Low	i Rating by David Novak at Raymond James
3/3/2020	HC Wainwright	Reiterated Rating	Buy	$65.00 ➝ $60.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
2/20/2020	HC Wainwright	Reiterated Rating	Buy	$65.00	Low	i Rating by D. Chattopadhyay at HC Wainwright
2/3/2020	Stifel Nicolaus	Boost Price Target	Buy	$45.00 ➝ $70.00	Medium	i Rating by Stephen Willey at Stifel Nicolaus
1/15/2020	Wells Fargo & Company	Reiterated Rating	Overweight	$48.00 ➝ $58.00	Low	i
1/14/2020	Raymond James	Reiterated Rating	Buy	$60.00	Low	i Rating by David Novak at Raymond James
1/10/2020	Wolfe Research	Initiated Coverage	Outperform	$61.00	High	i
12/9/2019	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$43.00	High	i
11/27/2019	Guggenheim	Initiated Coverage	Buy	$48.00	Low	i Rating by Etzer Darout at Guggenheim
11/25/2019	Raymond James	Boost Price Target	Strong-Buy	$40.00 ➝ $60.00	Low	i Rating by David Novak at Raymond James
11/25/2019	HC Wainwright	Initiated Coverage	Buy	$65.00	High	i Rating by D. Chattopadhyay at HC Wainwright
11/21/2019	Stifel Nicolaus	Reiterated Rating	Buy		High	i Rating by Stephen Willey at Stifel Nicolaus
11/19/2019	Guggenheim	Initiated Coverage	Buy	$48.00	Medium	i
11/7/2019	Raymond James	Set Price Target	Strong-Buy	$40.00	High	i Rating by David Novak at Raymond James
10/29/2019	Raymond James	Set Price Target	Strong-Buy	$40.00	Low	i Rating by David Novak at Raymond James
10/17/2019	Raymond James	Reiterated Rating	Strong-Buy	$40.00	Low	i Rating by David Novak at Raymond James
9/30/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$36.00 ➝ $40.00	High	i
9/27/2019	Raymond James	Set Price Target	Outperform	$36.00	High	i
8/30/2019	Stifel Nicolaus	Initiated Coverage	Buy	$45.00	High	i
8/27/2019	Citigroup	Boost Price Target	Buy	$22.00 ➝ $49.00	Medium	i
8/7/2019	Raymond James	Set Price Target	Outperform	$36.00	Low	i
8/5/2019	Barclays	Boost Price Target	Equal Weight	$15.00 ➝ $23.00	Medium	i
7/31/2019	Raymond James	Set Price Target	Outperform	$36.00	Medium	i
7/18/2019	Raymond James	Reiterated Rating	Outperform	$36.00	Low	i
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$34.00	Medium	i
5/30/2019	Raymond James	Reiterated Rating	Outperform	$36.00	High	i
5/15/2019	Raymond James	Set Price Target	Outperform	$36.00	Low	i
5/3/2019	Canaccord Genuity	Set Price Target	Buy	$23.00	Low	i Rating by Arlinda Lee at Canaccord Genuity
5/3/2019	Raymond James	Set Price Target	Outperform	$36.00	Low	i
4/26/2019	Raymond James	Boost Price Target	Outperform	$29.00 ➝ $36.00	Low	i
4/22/2019	Wells Fargo & Company	Boost Price Target	Outperform	$37.00 ➝ $42.00	Low	i
3/14/2019	Raymond James	Set Price Target	Outperform	$29.00	Medium	i
3/8/2019	Raymond James	Reiterated Rating	Outperform	$29.00	Low	i
12/10/2018	Raymond James	Set Price Target	Outperform	$29.00	Medium	i Rating by David Novak at Raymond James
11/28/2018	Raymond James	Boost Price Target	Outperform	$27.00 ➝ $29.00	High	i Rating by David Novak at Raymond James
11/28/2018	Canaccord Genuity	Set Price Target	Buy	$21.00	High	i Rating by Arlinda Lee at Canaccord Genuity
10/15/2018	Raymond James	Set Price Target	Outperform	$27.00	Low	i Rating by David Novak at Raymond James
9/5/2018	Raymond James	Set Price Target	Buy	$27.00	Low	i Rating by David Novak at Raymond James
9/5/2018	Canaccord Genuity	Set Price Target	Buy	$21.00	Low	i Rating by Arlinda Lee at Canaccord Genuity
8/15/2018	Raymond James	Reiterated Rating	Buy	$27.00	Low	i
8/2/2018	Citigroup	Upgrade	Neutral ➝ Buy	$19.00	High	i
6/21/2018	Citigroup	Lower Price Target	Neutral ➝ Neutral	$20.00 ➝ $19.00	Low	i
6/6/2018	Citigroup	Downgrade	Buy ➝ Neutral		High	i
6/5/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$22.00 ➝ $27.00	Medium	i
6/4/2018	Wells Fargo & Company	Boost Price Target	Outperform ➝ Outperform	$20.00 ➝ $37.00	Medium	i
5/18/2018	Raymond James	Boost Price Target	Outperform	$18.00 ➝ $22.00	Low	i
5/16/2018	Canaccord Genuity	Boost Price Target	Buy	$18.00 ➝ $21.00	Medium	i
5/14/2018	LADENBURG THALM/SH SH	Initiated Coverage	Buy	$25.00	Low	i
5/11/2018	Barclays	Upgrade	Underweight ➝ Equal Weight	$8.00 ➝ $15.00	High	i
3/19/2018	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$18.00	Low	i
9/30/2017	Cormark	Reiterated Rating	Buy		Medium	i
9/7/2017	Barclays	Reiterated Rating	Overweight ➝ Underweight	$8.00	High	i
5/23/2017	Citigroup	Initiated Coverage	Buy ➝ Buy	$18.00	Low	i
5/23/2017	Wells Fargo & Company	Initiated Coverage	Outperform ➝ Outperform	$20.00	Low	i
5/23/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$18.00	Low	i
5/23/2017	Barclays	Initiated Coverage	Overweight ➝ Overweight	$20.00	Low	i

(Data available from 3/3/2016 forward)

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $34.16

$33.90

$37.02

50 Day Range

MA: $43.83

$33.82

$56.25

52 Week Range

Now: $34.16

$20.33

$59.03

Volume

321,012 shs

Average Volume

606,410 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street research analysts have issued reports on Zymeworks in the last year: Barclays PLC, Bloom Burton, Canaccord Genuity, Citigroup Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Paradigm Capital, Raymond James, SVB Leerink LLC, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

9 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $51.11, suggesting a possible upside of 39.6%. Raymond James has the highest price target set, predicting ZYME will reach $74.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $38.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 3 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYME will outperform the market and that investors should add to their positions of Zymeworks.
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

Other companies that are similar to Zymeworks include GW Pharmaceuticals, Evotec, Allakos, Atea Pharmaceuticals, Maravai LifeSciences, TG Therapeutics, Perrigo, Blueprint Medicines, Turning Point Therapeutics, Galapagos, Emergent BioSolutions, Biohaven Pharmaceutical, Sage Therapeutics, Eidos Therapeutics and Arena Pharmaceuticals.

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company's listed phone number is 604-678-1388 and its investor relations email address is [email protected] The official website for Zymeworks is www.zymeworks.com.

NYSE:ZYME - Zymeworks Stock Price Target and Predictions

Analyst Price Target for ZYME

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

What is the current price target for Zymeworks?

What is the current consensus analyst rating for Zymeworks?

What other companies compete with Zymeworks?

How do I contact Zymeworks' investor relations team?